Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
AssigneeThe Catholic University of America
InventorsVenigalla B. Rao, Jingen Zhu
Life of this patent
Estimating the term…
Abstract
Described is hybrid viral vector comprising: a first virus such as bacteriophage T4; one or more second virus such as adeno-associated virus (AAV) attached to the first virus through cross-bridges, such as avidin-biotin cross-bridges; one or more DNA molecules packaged in the first virus; one or more nucleic acid molecules packaged in the second virus; and one or more proteins displayed on the surface of the first virus. Also described are methods of making and using such a hybrid viral vector.
Claims4
A product comprising:
- a first viral vector;
- one or more double stranded DNA molecules packaged in the first viral vector;
- a second viral vector;
- one or more nucleic acid molecules comprising single stranded DNA, double stranded DNA or RNA packaged in the second viral vector;
- and
- a cross-bridge connecting the second viral vector to the first viral vector;
- wherein the first viral vector is a prokaryotic viral vector;
- and
- wherein the second viral vector is a eukaryotic viral vector.
A product comprising:
- a first viral vector;
- one or more proteins displayed on the surface of the first viral vector
- a second viral vector;
- and
- a cross-bridge connecting the second viral vector to the first viral vector;
- wherein the first viral vector is a prokaryotic viral vector;
- wherein the second viral vector is a eukaryotic viral vector;
- and
- wherein the product, when exposed to cells of a biological specimen, delivers proteins into the cells of the biological specimen.
A method of treating a biological specimen, the method comprising:
- administering to the biological specimen a first viral vector;
- a second viral vector;
- and
- a cross-bridge connecting the second viral vector to the first viral vector;
- wherein the first viral vector is a prokaryotic viral vector;
- wherein the second viral vector is a eukaryotic viral vector;
- and
- wherein the route of administration is selected from the group consisting of:
- mixing, orally ingesting, by inhalation, subcutaneous migration, intramuscular injection, intravenous injection, transdermal migration, intranasal inhalation, rectal insertion, ocular, topical migration, sublingual, or buccal.
Dependencies are inferred from the claim text.